公开(公告)号：WO2019077125A1

公开(公告)日：2019-04-25

申请号：PCT/EP2018/078750

申请日：2018-10-19

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA" ,  IMPERIAL COLLEGE LONDON ,  HOSPITAL UNIVERSITARI DE GIRONA DOCTOR JOSEP TRUETA

Inventor： BURCELIN, Rémy ,  FEDERICI, Massimo ,  HOYLES, Lesley ,  DUMAS, Marc-Emmanuel ,  BARTON, Richard Hadlow ,  FERNANDEZ-REAL, José Manuel

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2800/085 ,  G01N2800/7052 ,  G01N2800/7085

Abstract: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition often observed in obese patients. Here, the inventors showed that plasma levels of phenylacetic acid (PAA, a metabolite resulting from microbial proteolysis associated with steatosis) correlates with steatosis and induces lipid accumulation and BCAA utilization in primary human hepatocytes and to some extent in mice. Accordingly, this metabolite could be used as a biomarker of NAFLD for stratifying the patients according to their risk.

公开(公告)号：WO2014064528A2

公开(公告)日：2014-05-01

申请号：PCT/IB2013/002652

申请日：2013-11-27

Applicant: 公益財団法人東京都医学総合研究所 ,  明治薬科大学

Inventor： 櫻庭　均 ,  芝崎　太 ,  中野　早知栄

IPC: G01N33/573

CPC classification number: G01N33/573 ,  G01N2333/94 ,  G01N2458/10 ,  G01N2800/7085

Abstract: 【課題】血液、血清、血漿中、または細胞や組織中において、α‐ガラクトシダーゼ濃度を測定する新規な方法を提供すること。 【解決手段】血液、血清、血漿中、または細胞や組織中において、MUSTag法を用いて、α‐ガラクトシダーゼ濃度を測定する。

Abstract translation: [问题]提供一种测定血液，血清，血浆，细胞或组织中α-半乳糖苷酶浓度的新方法。 [解决方案]使用MUSTag测定法测量血液，血清，血浆，细胞或组织中α-半乳糖苷酶的浓度。

公开(公告)号：WO2016207391A1

公开(公告)日：2016-12-29

申请号：PCT/EP2016/064736

申请日：2016-06-24

Applicant: METANOMICS HEALTH GMBH

Inventor： KAMLAGE, Beate ,  RESZKA, Regina ,  SCHATZ, Philipp ,  DOSTLER, Martin ,  CARVALHO, Susan ,  PETER, Erik ,  MAPPES, Philipp ,  KALTHOFF, Holger ,  SCHNIEWIND, Bodo ,  MAYERLE, Julia ,  LERCH, Markus ,  GRUETZMANN, Robert ,  PILARSKY, Christian

IPC: G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57438 ,  G01N33/6806 ,  G01N33/6812 ,  G01N2405/08 ,  G01N2800/60 ,  G01N2800/7028 ,  G01N2800/7076 ,  G01N2800/7085

Abstract: The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,C24:0) or ceramide (d18:2,C24:0), preferably being ceramide (d18:1,C24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,C16:0), sphingomyelin (41 :2) or sphingomyelin (d18:2,C17:0), preferably being sphingomyelin (35:1); and (iv) CA19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods.

Abstract translation: 本发明涉及一种用于诊断受试者的胰腺癌的方法，包括以下步骤：（a）在所述受试者的至少一个样品中测定一组诊断性生物标志物的量，所述诊断生物标志物组包含（i）至少一种诊断性氨基酸， 所述诊断性氨基酸为脯氨酸，组氨酸或色氨酸，优选为脯氨酸; （ii）至少一种诊断性神经酰胺，所述诊断性神经酰胺为神经酰胺（d18：1，C24：0）或神经酰胺（d18：2，C24：0），优选为神经酰胺（d18：1，C24：0）; （iii）至少一种诊断性鞘磷脂，所述诊断性鞘磷脂是鞘磷脂（35:1），鞘磷脂（d17：1，C16：0），鞘磷脂（41：2）或鞘磷脂（d18：2，C17：0） 是鞘磷脂（35：1）; 和（iv）CA19-9; 和（b）将所述诊断生物标志物的量与参考文献进行比较，由此诊断胰腺癌。 此外，本发明涉及一种用于确定受试者患有胰腺癌的可能性的方法以及与所述方法相关的装置和用途。

公开(公告)号：WO2014205109A3

公开(公告)日：2015-02-26

申请号：PCT/US2014042997

申请日：2014-06-18

Applicant: UNIV WAKE FOREST HEALTH SCIENCES ,  RUDEL LAWRENCE L

Inventor： RUDEL LAWRENCE L

IPC: A61K48/00 ,  C07D401/14 ,  C07D493/04 ,  C12N15/11 ,  C12Q1/60

CPC classification number: A61K31/4433 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/30 ,  C12Y203/01026 ,  G01N33/92 ,  G01N2800/52 ,  G01N2800/7085

Abstract: Compositions and methods for the treatment and management of steatosis are disclosed. Specifically, the disclosure provides compositions and methods for the treatment and management of fatty liver disorders, particularly those associated with a lysosomal acid lipase (LAL) deficiency, by administration of an effective amount of a steroyl-O-acyltransferase inhibitor, the inhibitor being effective to reduce cholesterol ester accumulation.

Abstract translation: 公开了用于治疗和管理脂肪变性的组合物和方法。 具体地，本公开提供了通过施用有效量的甾醇-O-酰基转移酶抑制剂来治疗和管理脂肪肝病症，特别是与溶酶体酸性脂肪酶（LAL）缺乏相关的组合物和方法，所述抑制剂是有效的 以减少胆固醇酯积累。

公开(公告)号：WO2014036182A2

公开(公告)日：2014-03-06

申请号：PCT/US2013057148

申请日：2013-08-28

Applicant: CALIFORNIA INST OF TECHN

Inventor： HSIAO ELAINE ,  MAZMANIAN SARKIS K ,  PATTERSON PAUL H ,  MCBRIDE SARA

IPC: A61K39/395 ,  A61K35/74 ,  G01N33/68

CPC classification number: A61K39/3955 ,  A61K35/74 ,  A61K35/741 ,  A61K2039/505 ,  C07K16/18 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/7076 ,  G01N2800/7085

Abstract: Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.

Abstract translation: 本文公开了用于诊断和治疗患有焦虑，自闭症谱系障碍（ASD）或具有一种或多种ASD症状的病理状况的受试者的组合物，系统和方法。

公开(公告)号：WO2015095451A1

公开(公告)日：2015-06-25

申请号：PCT/US2014/071035

申请日：2014-12-18

Applicant: METABOLON, INC.

Inventor： WATKINS, Steven, M.

IPC: A61K35/60 ,  A61P35/04 ,  G01N33/50

CPC classification number: G01N33/92 ,  G01N2405/00 ,  G01N2800/7085

Abstract: Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression/regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.

Abstract translation: 提供与新生脂肪生成有关的生物标志物，以及在索引中使用这些生物标志物评估DNL的方法。 此外，还提供了诊断，确定与DNL相关疾病的倾向和监测进展/退化的方法。 还提供了监测与DNL相关疾病的治疗功效以及基于DNL生物标志物的其它方法的方法。

公开(公告)号：WO2014064528A3

公开(公告)日：2015-01-15

申请号：PCT/IB2013002652

申请日：2013-11-27

Applicant: TOKYO METROPOLITAN ORG MED RES ,  MEIJI PHAMACEUTICAL UNIVERSITY

Inventor： SAKURABA HITOSHI ,  SHIBASAKI FUTOSHI ,  NAKANO SACHIE

IPC: G01N33/573

CPC classification number: G01N33/573 ,  G01N2333/94 ,  G01N2458/10 ,  G01N2800/7085

Abstract: [Problem] To provide a novel method for measuring the concentration of α-galactosidase in blood, blood serum, blood plasma, cells or tissue. [Solution] The concentration of α-galactosidase in blood, blood serum, blood plasma, cells or tissue is measured using a MUSTag assay.

Abstract translation: [问题]提供一种测定血液，血清，血浆，细胞或组织中α-半乳糖苷酶浓度的新方法。 [解决方案]使用MUSTag测定法测量血液，血清，血浆，细胞或组织中α-半乳糖苷酶的浓度。

公开(公告)号：WO2013144325A1

公开(公告)日：2013-10-03

申请号：PCT/EP2013/056790

申请日：2013-03-28

Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN

Inventor： SWINNEN, Johannes ,  BAGADI, Muralidhara Rao ,  MACHIELS, Jelle ,  BERKERS, Johannes ,  RINCON, Natalie Rueda ,  DEHAIRS, Jonas ,  MARIEN, Eyra ,  LERUT, Evelyne

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/57438 ,  G01N2333/60 ,  G01N2333/91057 ,  G01N2800/7085

Abstract: Methods and compositions are provided for the diagnosis and treatment of cancers, for example, renal cell cancer, prostate cancer, gastrointestinal cancer, and colorectal cancer. The methods and compositions are related to the fatty acyl chain elongation phenotypes observed in various tumors, such as the fatty acyl chain elongation mediated by the genes of the elongation pathway.

Abstract translation: 提供了用于诊断和治疗癌症的方法和组合物，例如肾细胞癌，前列腺癌，胃肠癌和结肠直肠癌。 方法和组合物与在各种肿瘤中观察到的脂肪酰基链延长表型有关，例如由延伸途径的基因介导的脂肪酰基链延长。

公开(公告)号：WO2016130961A1

公开(公告)日：2016-08-18

申请号：PCT/US2016/017822

申请日：2016-02-12

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： DENNIS, Edward, A. ,  QUEHENBERGER, Oswald ,  LOOMBA, Rohit

IPC: G01N33/92 ,  G01N33/48 ,  G01N33/49 ,  G01N33/50

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N33/88 ,  G01N2405/00 ,  G01N2570/00 ,  G01N2800/085 ,  G01N2800/7085

Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample. The disclosure provides a method of differentiating nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) in a subject. The method includes obtaining a biological sample from the subject; treating the sample with an alkaline solution to release esterified eicosanoids and recovering the eicosanoids; and comparing the levels of at least one esterified eicosanoid in the biological sample obtained from the subject to a control sample obtained from a NAFL subject, wherein a difference in the levels of the at least one eicosanoid in the sample obtained from the subject compared to the control is indicative of NASH.

Abstract translation: 本公开提供了用于区分非酒精性脂肪肝疾病和非酒精性脂肪性肝炎的方法。 该方法包括测量生物样品中的类二十烷酸和脂肪酸水平。 本公开提供了在受试者中区分非酒精性脂肪性肝炎（NASH）与非酒精性脂肪肝（NAFL）的方法。 该方法包括从受试者获得生物样品; 用碱性溶液处理样品以释放酯化的类花生酸并回收类花生酸; 并将从受试者获得的生物样品中的至少一种酯化类花生酸的水平与从NAFL受试者获得的对照样品进行比较，其中从受试者获得的样品中的至少一种类花生酸的水平与 控制指示NASH。

公开(公告)号：WO2014205109A2

公开(公告)日：2014-12-24

申请号：PCT/US2014/042997

申请日：2014-06-18

Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES ,  RUDEL, Lawrence, L.

Inventor： RUDEL, Lawrence, L.

IPC: A61K48/00

CPC classification number: A61K31/4433 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/30 ,  C12Y203/01026 ,  G01N33/92 ,  G01N2800/52 ,  G01N2800/7085

Abstract: Compositions and methods for the treatment and management of steatosis are disclosed.

Abstract translation: 公开了用于治疗和管理脂肪变性的组合物和方法。